Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28798620 | 0.90 | CYP19A1 (0.40) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL2648843 | 0.87 | CYP19A1 (0.35) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL7739960 | 0.83 | CYP19A1 (0.40) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL16700622 | 0.82 | CYP17A1 (0.41) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL9791620 | 0.82 | CYP19A1 (0.39) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL7268446 | 0.80 | CYP19A1 (0.38) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL7712264 | 0.77 | CYP19A1 (0.39) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL1406898 | 0.76 | CYP19A1 (0.47) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL28269017 | 0.73 | TBXAS1 (0.45) | CYP19A1CYP17A1 | |
| Methane SCHEMBL27640067 | 0.72 | CYP17A1 (0.44) | CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | claimed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | claimed |
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| CN-102775437-A | Carbon dioxide transition metal complex, preparation method and application thereof | UNIV NORTHWESTERN | 2012-11-14 | — | — | CN | claimed |
| US-7960440-B2 | Highly dispersible carbon nanospheres in an organic solvent and methods for making same | HEADWATERS TECHNOLOGY INNOVATION LLC (US) | 2011-06-14 | — | — | US | claimed |
| WO-2009085365-A1 | HIGHLY DISPERSIBLE CARBON NANOSPHERES IN AN ORGANIC SOLVENT AND METHODS FOR MAKING SAME | HEADWATERS TECHNOLOGY INNOVATION, LLC (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090093554-A1 | HIGHLY DISPERSIBLE CARBON NANOSPHERES IN AN ORGANIC SOLVENT AND METHODS FOR MAKING SAME | HEADWATERS TECHNOLOGY INNOVATION, LLC (US) | 2009-04-09 | — | — | US | claimed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12391673-B2 | LANCL ligands | NIMMUNE BIOPHARMA, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-115403608-B | Spirofluorene silicon compound and electroluminescent application thereof | 上海天马微电子有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | ENANTA PHARM INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-86108027-A | Prepare new 2,2 '-method of Lian-1H-imidazoles | — | 1987-10-07 | — | — | CN | disclosed |
| EP-0229922-A2 | Novel 2,2'-BI-1H-imidazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0222598-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1987-05-20 | — | — | EP | disclosed |
| US-4469865-A | INHIBITORS OF THROMBOXANE SYNTHETASE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-09-04 | — | — | US | disclosed |
| US-4461905-A | THROMBOXANE SYNTHETASE INHIBITOR INTERMEDIATE | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
| EP-0076140-A2 | 1,3-Disubstituted imidazoles and a process for their production | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | CYP19A1 2426/4885NFKB1 4761/4885QPCT 1318/4885 |
| US-12391673-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | CYP19A1 4071/4885NFKB1 1309/4885QPCT 1734/4885 |
| US-20240366538-A1 | Hepatitis B Antiviral Agents | HAVCR2, PYGL, SLC10A1 | CYP19A1 1465/4885NFKB1 392/4885QPCT 499/4885 |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | MLX, LDHA, CA2 | CYP19A1 2426/4885NFKB1 4761/4885QPCT 1318/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | CYP19A1 1465/4885NFKB1 392/4885QPCT 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.